AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Food for chewing
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Drooling
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Sleep disturbances
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Irritability
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Canine eruption
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Low grade increases in body temperature
Number of subjects: 270
Study 26215351 — intervention group
Group type: COMPARATOR
Intervention: Fever
Number of subjects: 270
Study 23692975 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine® oral rinse twice daily
Number of subjects: 398
Study 23692975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate oral rinse 2/24
Number of subjects: 398
Study 23692975 — intervention group
Group type: COMPARATOR
Intervention: Sterile water 2/24 (control group)
Number of subjects: 398
Study 23692975 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 398
Study 21718471 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 month intensive inpatient treatment program during weekdays, followed by six monthly return visits of 2 days (Group A)
Number of subjects: 80
Study 21718471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 month intensive inpatient treatment program during weekdays, followed by biweekly return visits of 2 days during the next four months, followed by six monthly return visits of 2 days (Group B)
Number of subjects: 80
Study 21718471 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 80
Study 21718471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Group A and Group B
Number of subjects: 80
Study 19092694 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice powder concentrate (JPC) 70%
Number of subjects: 41
Study 19092694 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice powder concentrate (JPC) 80%
Number of subjects: 41
Study 19092694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac) 70%
Number of subjects: 41
Study 19092694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac) 80%
Number of subjects: 41
Study 19092694 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 80% .VO2max
Number of subjects: 41
Study 17105987 — intervention group
Group type: EXPERIMENTAL
Intervention: Very obese patients (BMI >= 35 kg/m2)
Number of subjects: 4288
Study 17105987 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight patients (BMI < 18.5 kg/m2)
Number of subjects: 4288
Study 12775279 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surveillance followed by radical retropubic prostatectomy (mean 23.4 months, range 8‐55 months)
Number of subjects: 26
Study 12775279 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery without prior surveillance (matched control group)
Number of subjects: 26
Study 11248828 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 17
Study 11248828 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine
Number of subjects: 17
Study 11248828 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 17
Study 11248828 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine + 4% lidocaine
Number of subjects: 17
Study 11248828 — intervention group
Group type: COMPARATOR
Intervention: 0.5% tetracaine + 0.75% bupivacaine
Number of subjects: 17
Study 9892788 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 317
Study 9892788 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 317
Study 8010153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 0
Study 8010153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical techniques balancing acceptance and change
Number of subjects: 0
Study 2643237 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaxon tablets
Number of subjects: 12
Study 2643237 — intervention group
Group type: COMPARATOR
Intervention: Valium tablets
Number of subjects: 12
Study 23150917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice A
Number of subjects: 43
Study 23150917 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice B
Number of subjects: 43
Study 7380205 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg/day)
Number of subjects: 15
Study 7380205 — intervention group
Group type: COMPARATOR
Intervention: Control (furosemide or paracentesis)
Number of subjects: 15
Study 30767761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of SiMYB3 in transgenic Arabidopsis plants
Number of subjects: 6
Study 30767761 — intervention group
Group type: COMPARATOR
Intervention: Control plants (non-transgenic Arabidopsis)
Number of subjects: 6
Study 29446442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified vaccinated donors
Number of subjects: 0
Study 29446442 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified convalescent donors
Number of subjects: 0
Study 29446442 — intervention group
Group type: COMPARATOR
Intervention: Control donors
Number of subjects: 0
Study 27347034 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules
Number of subjects: 60
Study 27347034 — intervention group
Group type: COMPARATOR
Intervention: Conservative or hormone therapy
Number of subjects: 60
Study 24684853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-tempered water (3 °C)
Number of subjects: 12
Study 24684853 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-tempered water (22 °C)
Number of subjects: 12
Study 24684853 — intervention group
Group type: COMPARATOR
Intervention: Body-tempered water (37 °C)
Number of subjects: 12
Study 22413874 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256
Study 22413874 — intervention group
Group type: COMPARATOR
Intervention: DRV/r plus two NRTIs
Number of subjects: 256
Study 22413874 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (strict ITT analysis)
Number of subjects: 256
Study 22413874 — intervention group
Group type: COMPARATOR
Intervention: DRV/r plus two NRTIs (strict ITT analysis)
Number of subjects: 256
Study 22413874 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 256
Study 21059484 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 mg dabigatran
Number of subjects: 3623
Study 21059484 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran
Number of subjects: 3623
Study 21059484 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 3623
Study 17995698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie muffins (LCMs)
Number of subjects: 14
Study 17995698 — intervention group
Group type: COMPARATOR
Intervention: Plain muffins (PMs)
Number of subjects: 14
Study 17995698 — intervention group
Group type: COMPARATOR
Intervention: Bread
Number of subjects: 14
Study 16246655 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal contraceptive ring
Number of subjects: 201
Study 16246655 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive
Number of subjects: 201
Study 12010270 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological filter (Supor, Pall Life Sciences)
Number of subjects: 336
Study 12010270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filter)
Number of subjects: 336
Study 9647138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (30,000 KIU/kg)
Number of subjects: 96
Study 9647138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (15,000 KIU/kg)
Number of subjects: 96
Study 9647138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin with additional bolus
Number of subjects: 96
Study 8702066 — intervention group
Group type: EXPERIMENTAL
Intervention: Early growth modification treatment for Class II malocclusion (duration: 15 months)
Number of subjects: 208
Study 2198057 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax prebrushing rinse
Number of subjects: 103
Study 2198057 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 103
Study 343994 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine-N-(cyclopropyl methyl) bromide (DA 3177) at doses of 2.5 mg and 5 mg i.v.
Number of subjects: 8
Study 343994 — intervention group
Group type: COMPARATOR
Intervention: hyoscine-N-butyl bromide at doses of 10 mg and 20 mg i.v.
Number of subjects: 8
Study 31654487 — intervention group
Group type: COMPARATOR
Intervention: Evobrutinib (single dose: 25, 50, 100, 200, 350, and 500 mg)
Number of subjects: 84
Study 31654487 — intervention group
Group type: COMPARATOR
Intervention: Evobrutinib (multiple dosing: 25, 75, and 200 mg/day for 14 days)
Number of subjects: 84
Study 31654487 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib (≥ 200 mg single dose)
Number of subjects: 84
Study 31654487 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib (≥ 100 mg)
Number of subjects: 84
Study 31654487 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib (25 mg multiple dosing)
Number of subjects: 84
Study 31654487 — intervention group
Group type: COMPARATOR
Intervention: Evobrutinib
Number of subjects: 84
Study 28946799 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning
Number of subjects: 0
Study 28946799 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0
Study 29105625 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin'gangteng capsule combined with Kangfuxiaoyan suppository
Number of subjects: 97
Study 29105625 — intervention group
Group type: COMPARATOR
Intervention: Kangfuxiaoyan suppository
Number of subjects: 97
Study 26294526 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches based on physiological response, eye tracking, and user movement analysis
Number of subjects: 0
Study 23413101 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 150 to 375 mg subcutaneously every 2 or 4 weeks from week 0 to 48
Number of subjects: 0
Study 23413101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20680676 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced profiles (n=74)
Number of subjects: 103
Study 20680676 — intervention group
Group type: COMPARATOR
Intervention: Basic profiles (n=29)
Number of subjects: 103
Study 19231138 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg intranasal diazepam (DZP)
Number of subjects: 8
Study 19231138 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg intranasal diazepam (DZP)
Number of subjects: 8
Study 19231138 — intervention group
Group type: COMPARATOR
Intervention: 5mg intravenous diazepam (DZP injectable, 5mg/mL)
Number of subjects: 8
Study 17268414 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring diet (150 g baked herring fillets/day, 5 days/week)
Number of subjects: 15
Study 17268414 — intervention group
Group type: COMPARATOR
Intervention: Reference diet (pork and chicken fillets)
Number of subjects: 15
Study 15141407 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic placement
Number of subjects: 43
Study 15141407 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic placement
Number of subjects: 43
Study 11793034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 128
Study 11793034 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 128
Study 9382049 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg a day for 1 month and amoxycillin 1 g three times daily for 14 days
Number of subjects: 16
Study 9382049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study 8369641 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg d,l‐fenfluramine (FEN)
Number of subjects: 15
Study 8369641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3519046 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-38,485 (specific thromboxane synthetase inhibitor)
Number of subjects: 25
Study 3519046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31609920 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned group (oxytocin nasal spray with a distinctive smell)
Number of subjects: 99
Study 31609920 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo spray)
Number of subjects: 99
Study 31609920 — intervention group
Group type: COMPARATOR
Intervention: Drug control group (oxytocin spray)
Number of subjects: 99
Study 30757911 — intervention group
Group type: EXPERIMENTAL
Intervention: Linfadren® plus conventional treatment
Number of subjects: 60
Study 30757911 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study 28273084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D deficient children
Number of subjects: 960
Study 28273084 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-D replete children
Number of subjects: 960
Study 28273084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D status (deficient vs replete)
Number of subjects: 960
Study 25331203 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine at a dose of 2.5 mg · kg(‐1)
Number of subjects: 36
Study 25331203 — intervention group
Group type: COMPARATOR
Intervention: TAP block with bupivacaine at a dose of 1.25 mg · kg(‐1)
Number of subjects: 36
Study 23632722 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/d vitamin D3
Number of subjects: 132
Study 23632722 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D3
Number of subjects: 132
Study 23632722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/d vitamin D3
Number of subjects: 132
Study 23632722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/d vitamin D3
Number of subjects: 132
Study 23632722 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages (400, 800, 1200, 1600 IU/d)
Number of subjects: 132
Study 21122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 24
Study 21122992 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 24
Study 18268396 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a) administered for 6 days starting 1 week before nephrectomy.
Number of subjects: 60
Study 18268396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with IFN-alpha2a).
Number of subjects: 60
Study 18268396 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (IFN-alpha2a).
Number of subjects: 60
Study 17133610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone and 6 infusions (monthly) of intravenous cyclophosphamide (CYC) followed by oral azathioprine (AZA)
Number of subjects: 45
Study 17133610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14604034 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions detailing muscle physiology, neural control of muscle force, and imagery training
Number of subjects: 16
Study 14604034 — intervention group
Group type: COMPARATOR
Intervention: Educational sessions about health and fitness (Control)
Number of subjects: 16
Study 11203913 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Meridol mouthrinse
Number of subjects: 80
Study 11203913 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free Meridol mouthrinse
Number of subjects: 80
Study 8857479 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 10 mg bid
Number of subjects: 22
Study 8857479 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 1629507 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (600 micrograms, twice daily)
Number of subjects: 14
Study 1629507 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (375 micrograms, twice daily)
Number of subjects: 14
Study 6860201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% betaxolol ophthalmic solution
Number of subjects: 20
Study 6860201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (drug vehicle)
Number of subjects: 20
Study 31919749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil plus Chinese medicine (Tiaogan Jianpi Hexue and Tiaogan Jiedu Huashi)
Number of subjects: 590
Study 31919749 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil plus placebo (control group)
Number of subjects: 590
Study 30691922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral 0.5% moxifloxacin (0.03 mL, 150 μg)
Number of subjects: 3640
Study 30691922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IC medication)
Number of subjects: 3640
Study 30691922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral 0.5% moxifloxacin
Number of subjects: 3640
Study 28513523 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy for 2 weeks
Number of subjects: 160
Study 28513523 — intervention group
Group type: COMPARATOR
Intervention: Bismuth containing quadruple therapy for 2 weeks
Number of subjects: 160
Study 28513523 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 + 5 clarithromycin‐based sequential therapy
Number of subjects: 160
Study 28513523 — intervention group
Group type: COMPARATOR
Intervention: 7 + 7 clarithromycin‐based sequential therapy
Number of subjects: 160
Study 26037777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus ongoing methotrexate
Number of subjects: 553
Study 26037777 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab plus placebo
Number of subjects: 553
Study 26037777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab discontinuation
Number of subjects: 553
Study 26037777 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS28‐2 criteria
Number of subjects: 553
Study 23522322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion or cognitive intervention and exercises
Number of subjects: 93
Study 21644315 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion pretreatment (mild moxibustion applied at Guanyuan (CV 4), Zusanli (ST 36) or Guanyuan (CV 4), Sanyinjiao (SP 6) alternatively once daily for 4 weeks)
Number of subjects: 12
Study 21644315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 20108857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pressure (IMP) during isometric fatiguing extension at 60% of maximum voluntary contraction
Number of subjects: 30
Study 20108857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue oxygenation pressure (pO2) during isometric fatiguing extension
Number of subjects: 30
Study 20108857 — intervention group
Group type: EXPERIMENTAL
Intervention: Median frequency (MF) shift in the electromyographic power density spectrum during contraction
Number of subjects: 30
Study 16454794 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Control): No restoration
Number of subjects: 50
Study 16454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Unrestored teeth
Number of subjects: 50
Study 16454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Restored with composite resin (AP‐X; Kuraray, Japan)
Number of subjects: 50
Study 16454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: Restored with composite resin and polyethylene woven fibre (Ribbond) placed in a groove
Number of subjects: 50
Study 16454794 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5: Cavity surfaces covered with flowable resin and polyethylene fibre placed into the bed of resin before composite restoration
Number of subjects: 50
Study 15288698 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA infusion
Number of subjects: 15
Study 15288698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15288698 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CBF between young and old subjects
Number of subjects: 15
Study 11135717 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.10μg · kg‐1 min‐1
Number of subjects: 0
Study 11135717 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 0
Study 8290916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin 70 mg/m2 and doxorubicin 30 mg/m2, 2 cycles with 3-week interval)
Number of subjects: 311
Study 8290916 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 311
Study 8290916 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 311
Study 8290916 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 311
Study 3565525 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook-based occupational therapy program
Number of subjects: 0
Study 3565525 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy
Number of subjects: 0
Study 29940980 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-point Global Rating of Change scale (GRC)
Number of subjects: 451
Study 29940980 — intervention group
Group type: EXPERIMENTAL
Intervention: five-point GRC
Number of subjects: 451
Study 29940980 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 451
Study 26468947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib at 750 mg
Number of subjects: 18
Study 26468947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib at 1,000 mg
Number of subjects: 18
Study 26468947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib at 1,250 mg
Number of subjects: 18
Study 26468947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib combined with Gemcitabine and Cisplatin (GC)
Number of subjects: 18
Study 24833726 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H₂O PEEP and one recruitment manoeuvre (RM) after induction and exsufflation
Number of subjects: 50
Study 24833726 — intervention group
Group type: COMPARATOR
Intervention: 10 cm H₂O PEEP (control group)
Number of subjects: 50
Study 24833726 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H₂O PEEP and one RM
Number of subjects: 50